The purpose of this study is to assess the long-term safety and tolerability of \[S,S\]-Reboxetine in patients with chronic painful diabetic peripheral neuropathy
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
136
\[S,S\]-reboxetine
Any standard of care treatment for DPN
Vital signs
Time frame: duration of study
Physical examination
Time frame: duration of study
12-lead ECG
Time frame: duration of study
Hematology/Biochemistry
Time frame: duration of study
Adverse events
Time frame: duration of study
Pain Visual Analogue Scale
Time frame: duration of study
Neuropathic Pain Symptom Inventory
Time frame: duration of study
Modified Brief Pain Inventory-Short Form
Time frame: duration of study
Patient Global Impression of Change
Time frame: duration of study
SF-12 Health Survey
Time frame: duration of study
EQ-5D
Time frame: duration of study
Analgesic Treatment Satisfaction Scale
Time frame: duration of study
Pain-related Medication Utilization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Scottsdale, Arizona, United States
Pfizer Investigational Site
Jonesboro, Arkansas, United States
Pfizer Investigational Site
Auburn, California, United States
Pfizer Investigational Site
Huntington Beach, California, United States
Pfizer Investigational Site
Orangevale, California, United States
Pfizer Investigational Site
Naples, Florida, United States
Pfizer Investigational Site
Winter Park, Florida, United States
...and 83 more locations
Time frame: duration of study